CR20140101A - Inmunoterapia contra el vhc - Google Patents

Inmunoterapia contra el vhc

Info

Publication number
CR20140101A
CR20140101A CR20140101A CR20140101A CR20140101A CR 20140101 A CR20140101 A CR 20140101A CR 20140101 A CR20140101 A CR 20140101A CR 20140101 A CR20140101 A CR 20140101A CR 20140101 A CR20140101 A CR 20140101A
Authority
CR
Costa Rica
Prior art keywords
against hcv
immunotherapy against
august
treated
hepatitis
Prior art date
Application number
CR20140101A
Other languages
English (en)
Inventor
Michel Morre
Brigitte Assouline
Thérèse Croughs
Pierre Demol
Stephanie Beq
Original Assignee
Cytheris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47628658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140101(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cytheris filed Critical Cytheris
Publication of CR20140101A publication Critical patent/CR20140101A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se refiere al uso de interleucina -7 (IL-7) para tratar hepatitis Cen un paciente infectado con el virus de la hepatitis C, en el que dicho paciente se ha tratado o está tratandose con un agente viral o una combinación de agentes antivirales que reduce la carga viral. Prioridad: 11306012.3 del 03 de agosto del 2011 y 61/514,915 del 04 de agosto del 2011. Publicación Internacional: WO 2013/017653 A1 del 07 de febrero del 2013.
CR20140101A 2011-08-03 2014-02-27 Inmunoterapia contra el vhc CR20140101A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11306012 2011-08-03
US201161514915P 2011-08-04 2011-08-04

Publications (1)

Publication Number Publication Date
CR20140101A true CR20140101A (es) 2014-05-26

Family

ID=47628658

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140101A CR20140101A (es) 2011-08-03 2014-02-27 Inmunoterapia contra el vhc

Country Status (18)

Country Link
US (1) US20140377218A1 (es)
EP (1) EP2739301B1 (es)
JP (1) JP2014521679A (es)
KR (1) KR20140063657A (es)
CN (1) CN103917240A (es)
AU (1) AU2012292032A1 (es)
BR (1) BR112014002365A2 (es)
CA (1) CA2843495A1 (es)
CL (1) CL2014000269A1 (es)
CR (1) CR20140101A (es)
EA (1) EA201490399A1 (es)
ES (1) ES2568755T3 (es)
IL (1) IL230669A0 (es)
MX (1) MX2014001355A (es)
PH (1) PH12014500283A1 (es)
SG (1) SG10201606395XA (es)
WO (1) WO2013017653A1 (es)
ZA (1) ZA201401986B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2708160C2 (ru) * 2015-06-11 2019-12-04 Дженексин, Инк. Модифицированный белок интерлейкина-7 и способы его применения
KR102386735B1 (ko) 2015-11-06 2022-04-14 주식회사 제넥신 변형된 인터루킨-7 융합 단백질의 제형
KR20170066265A (ko) 2015-12-04 2017-06-14 주식회사 제넥신 면역글로불린 Fc가 융합된 인터루킨-7 융합 단백질을 포함하는 사람 파필로마바이러스 유래 질환의 예방 또는 치료용 약학적 조성물
KR102604595B1 (ko) 2015-12-04 2023-11-21 주식회사 제넥신 면역글로불린 Fc가 융합된 인터루킨-7 융합 단백질을 포함하는 인플루엔자 바이러스 감염의 예방 또는 치료용 약학적 조성물
EP3439688A4 (en) * 2016-04-04 2020-05-27 The Regents of the University of California COMPOSITIONS AND METHODS IN CONNECTION WITH POLYCYTOTOXIC T CELLS
MX2022002277A (es) * 2019-09-04 2022-06-08 Genexine Inc Metodo para incrementar el conteo de linfocitos mediante el uso de proteina de fusion de interleucina 7 (il-7) en tumores.
CN116685345A (zh) * 2020-11-25 2023-09-01 杰科生物医药公司 Il-7融合蛋白及相关方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
ZA887773B (en) 1987-10-26 1989-07-26 Immunex Corp Interleukin-7
US5026687A (en) 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
CN1078478C (zh) 1993-02-24 2002-01-30 王瑞駪 活性抗病毒聚合物的组成及应用方法
CA2167537A1 (en) 1993-07-19 1995-02-02 Tsuneo Ozeki Hepatitis c virus proliferation inhibitor
DE4432623A1 (de) 1994-09-14 1996-03-21 Huels Chemische Werke Ag Verfahren zur Bleichung von wäßrigen Tensidlösungen
US5633388A (en) 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5830905A (en) 1996-03-29 1998-11-03 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US5891874A (en) 1996-06-05 1999-04-06 Eli Lilly And Company Anti-viral compound
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
UA61962C2 (uk) 1997-06-30 2003-12-15 Мерц Фарма Гмбх Унд Ко. Кгаа Сполука 1-аміноалкілциклогексану, фармацевтична композиція на її основі та спосіб лікування
EP1391513A1 (en) 2002-08-08 2004-02-25 Cytheris IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof
PT1699822E (pt) 2003-12-30 2008-07-30 Merck Patent Gmbh Proteínas de fusão de il-7
RU2437893C2 (ru) 2004-12-09 2011-12-27 Мерк Патент Гмбх Варианты il-7 со сниженной иммуногенностью
EP1746161A1 (en) 2005-07-20 2007-01-24 Cytheris Glycosylated IL-7, preparation and uses
CN101152567A (zh) * 2006-09-29 2008-04-02 上海新生源医药研究有限公司 重组人白介素-11的药物组合
MX2012001058A (es) 2009-07-31 2012-06-19 Ct Hospitalier Universitaire Vaudois Metodos para diagnosticar o predecir el resultado de hepatitis c en pacientes infectados con hcv.

Also Published As

Publication number Publication date
US20140377218A1 (en) 2014-12-25
ZA201401986B (en) 2015-07-29
SG10201606395XA (en) 2016-09-29
KR20140063657A (ko) 2014-05-27
EP2739301B1 (en) 2016-01-20
WO2013017653A1 (en) 2013-02-07
EP2739301A1 (en) 2014-06-11
PH12014500283A1 (en) 2014-03-31
BR112014002365A2 (pt) 2017-02-21
AU2012292032A1 (en) 2014-03-13
NZ620689A (en) 2016-03-31
IL230669A0 (en) 2014-03-31
CN103917240A (zh) 2014-07-09
CA2843495A1 (en) 2013-02-07
ES2568755T3 (es) 2016-05-04
JP2014521679A (ja) 2014-08-28
EA201490399A1 (ru) 2014-06-30
MX2014001355A (es) 2014-11-21
CL2014000269A1 (es) 2014-10-10
HK1202794A1 (zh) 2015-10-09

Similar Documents

Publication Publication Date Title
CL2012002489A1 (es) Compuestos derivados de sililo nafto-imidazol; composición farmacéutica; y su uso para prevenir o tratar una infección por el virus de la hepatitis c.
CL2015000870A1 (es) Análogos de 2' -cloro nucleósido para infección por vhc.
CO6761348A2 (es) Compuestos antivirales
UY32699A (es) Compuestos antivirales eficaces para inhibir la replicación del virus de la hepatitis c ("hcv"), procesos, composiciones, y métodos relacionados
CL2011002830A1 (es) Compuestos derivados de haloalquil heteroaril benzamidas; composicion farmaceutica uso de la composicion en el tratamiento de una infeccion viral, tal como el virus de la hepatitis b y c.
MD4841B1 (ro) Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică
UY32715A (es) Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
MX2011007195A (es) Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
MX2010005107A (es) Componente de silibinina para tratamiento contra hepatitis.
UY32720A (es) Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados
UY32721A (es) Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados
MX2013000242A (es) Tratamiento de enfermedades relacionadas con el virus de hepatitis c que usa hidroxicloroquina o una combinacion de hidroxicloroquina y un agente antiviral.
PH12016500465A1 (en) Deoxynojirimycin derivatives and methods of their using
EA201290373A1 (ru) Синергическая противовирусная композиция и ее применение
MX2017003117A (es) Particula tipo virus de flavivirus.
EA201490399A1 (ru) Иммунотерапия hcv (вируса гепатита c)
WO2013106689A8 (en) Hcv ns3 protease inhibitors
UY34420A (es) ?métodos de tratamiento del virus de la hepatitis c con que de gs-7977 y ribavirina, composiciones y usos"
CO7030958A2 (es) Compuestos sustituidos de bencilamina, su uso en medicina, y en particular en el tratamiento de la infección del virús de la hepatitis c (vch)
EA201170605A1 (ru) Циклоундекадепсипептидные соединения и применение указанных соединений в качестве лекарственного средства
MX2013003245A (es) Vacuna contra virus de diarrea viral de bovinos.
MX2014014878A (es) Combinacion de agentes terapueticos para tratar infeccion por el virus de la hepatitis c (hcv).
WO2009152519A3 (en) Novel antiviral peptides against influenza virus
AR084049A1 (es) Uso del pacap para el tratamiento de infecciones virales en organismos acuaticos
MX2019000645A (es) Uso de xibornol como agente activo en el tratamiento de infecciones virales.